A5101691318- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- Lymphoma Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Complement system in diseases
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Virus-based gene therapy research
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Multiple Myeloma Research and Treatments
- Blood groups and transfusion
- Antifungal resistance and susceptibility
- Pneumocystis jirovecii pneumonia detection and treatment
- Genomic variations and chromosomal abnormalities
Soochow University
2016-2025
First Affiliated Hospital of Soochow University
2016-2025
Shanghai First People's Hospital
2022-2024
Shanghai Jiao Tong University
2020-2024
Guangzhou Medical University
2024
Guangzhou Women and Children Medical Center
2024
National Clinical Research
2020-2024
Renji Hospital
2013-2024
Eighth Affiliated Hospital of Sun Yat-sen University
2024
Sun Yat-sen University
2024
Abstract CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR therapies have been developed to reduce the possibility of CD19-negative relapse; however, superior strategy is still uncertain. This study screened 219 patients with relapsed/refractory B-ALL who were enrolled in clinical trials either (NCT03919240) or (NCT03614858). The complete remission (CR) rates single...
Abstract The tumor burden (TB) is significantly related to the severity of cytokine release syndrome (CRS) caused by CAR-T cells, but its correlation with therapeutic efficacy has not been systematically studied. This study focused on effects TB level both safety and ssCART-19 as a treatment for r/r B-ALL. Taking 5% boundary, participants were divided into 2 groups, high low groups. Under this grouping strategy, impacts differential B-ALL TBs clinical (CR rate long-term survival) profiles...
Abstract Introduction Neuromyelitis optica spectrum disorders (NMOSD), mainly mediated by B cells and AQP4 antibody, has a high rate of recurrence. Telitacicept is novel drug specifically targeting the upstream signaling for activation cell with its following production autoimmune antibodies. Thus, it may be promising approach. Our study preliminarily explored potential safety effectiveness plasma exchange in treatment recurrent NMOSD. Methods This was single‐center, single‐arm, open‐label...
Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is small molecule that has been studied in several hematologic malignancies as both monotherapy combination with other agents. However, there little its use treatment APL or variant APL. In this report, we identified THRAP3 novel RARA fusion resembling APL, which was resistant to all-trans...
Cell viability assessment plays a crucial role in biological research, pharmaceutical development, and toxicological identification. Here, we used GelRed, sensitive safer nucleic acid dye, to selectively label dead cells with red fluorescence (FL) thus distinguishing from live ones. Further more, the combined use of GelRed SYTO 9 (another dye) enabled clear differentiation FL spectra between two physiological statuses. The concentrations were optimized obtain highest ratio cells. GelRed/SYTO...
Not available.
Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Ph-negative BCP-ALL) accounts for a significant portion of adult cases. Blinatumomab, bispecific T-cell engager, has shown efficacy in relapsed or refractory BCP-ALL, but its role induction therapy with reduced-dose chemotherapy is being explored. In this retrospective study, 35 newly diagnosed Ph-negative BCP-ALL patients received followed by two weeks blinatumomab (RDC-Blinatumomab-2W) as part our previous clinical...
Abstract Purpose: To assess the efficacy and safety of an induction regimen composed idarubicin, cytarabine, cladribine (IAC) in patients with de novo acute myeloid leukemia (AML). Patients Methods: Adult newly diagnosed AML were randomized to IAC group (cladribine 5 mg/m2/day for days, idarubicin 8 3 cytarabine 100 7 days) IA (idarubicin 12 days at a 1:2 ratio. The primary endpoint was complete remission (CR) after induction. Secondary endpoints included 2-year overall survival (OS),...
To investigate the efficacy of chemo-free regimen in treatment patients with treatment-naive Philadelphia chromosome positive mixed phenotype acute leukemia(Ph+MPAL). The clinical data newly treated Ph+MPAL who received venetoclax (VEN), azacytidine (AZA) and tyrosine kinase inhibitors (TKIs) First Affiliated Hospital Soochow University from July 1, 2021 to October 31, 2023 were retrospectively included. last follow-up date was December 2024. complete remission/complete remission incomplete...
Venetoclax (VEN)--based induction therapy has demonstrated considerable promise in treating acute myeloid leukemia (AML); however, the optimal VEN-based combination remains to be established. This study evaluated efficacy and safety of venetoclax-homoharringtonine-cytarabine (VHA) regimen patients with newly diagnosed (ND) AML. A retrospective analysis was conducted on 55 treated VHA regimen. The overall response rate (ORR) 92.7% (51/55, 95% CI 82%-98%), composite complete remission (CRc)...
<div>AbstractPurpose:<p>To assess the efficacy and safety of an induction regimen composed idarubicin, cytarabine, cladribine (IAC) in patients with <i>de novo</i> acute myeloid leukemia (AML).</p>Patients Methods:<p>Adult newly diagnosed AML were randomized to IAC group (cladribine 5 mg/m<sup>2</sup>/day for days, idarubicin 8 3 cytarabine 100 7 days) IA (idarubicin 12 days at a 1:2 ratio. The primary endpoint was complete remission (CR) after...